Latest news with #Hims&Hers
Associated Press
a day ago
- Business
- Associated Press
Hims & Hers Health, Inc. Investors Reminder: Kessler Topaz Meltzer & Check, LLP Reminds Hims & Hers Health, Inc. Shareholders of Deadline in Securities Fraud Class Action Lawsuit
RADNOR, PA - July 22, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ('Hims & Hers') ( NYSE: HIMS ) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is August 25, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Hims & Hers losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaints allege that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Please CLICK HERE to view our video or copy and paste this link into your browser: THE LEAD PLAINTIFF PROCESS: Hims & Hers investors may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Hims & Hers investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View the original release on
Business Insider
2 days ago
- Business
- Business Insider
HIMS Lawsuit Alert! Hims & Hers Faces Class Action Lawsuit After Wegovy Scandal
A class action lawsuit was filed against Hims & Hers (HIMS) by Levi & Korsinsky on June 25, 2025. The plaintiffs (shareholders) alleged that they bought HIMS stock at artificially inflated prices between April 29, 2025, and June 22, 2025 (Class Period) and are now seeking compensation for their financial losses. Investors who bought Hims & Hers stock during that period can click here to learn about joining the lawsuit. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Hims & Hers is an American telehealth platform that connects consumers with licensed healthcare professionals and medical treatments. Through the digital platform, consumers can obtain prescription medications, over-the-counter treatments, personal care products, and supplements. The company recently partnered with pharmaceutical giant Novo Nordisk (NVO) to offer its U.S. FDA-approved weight-loss drug Wegovy on the Hims & Hers platform. The company's claims about its partnership with Novo Nordisk and its future potential are at the heart of the current complaint. Hims & Hers' Misleading Claims According to the lawsuit, HIMS and two of its senior officers (the Defendants) repeatedly made false and misleading public statements throughout the Class Period. In particular, they are accused of omitting truthful information about the GLP-1 (glucagon-like peptide-1) injectables it makes available to consumers, and ancillary issues, from SEC filings and related material. During the Class Period, Hims & Hers announced that it had partnered with Novo Nordisk and that American consumers could start accessing 'NovoCare Pharmacy directly through the Hims & Hers platform, with a bundled offering of all dose strengths of Wegovy and a Hims & Hers membership.' This offering included 24/7 care, continued clinical support, and nutrition guidance, all under one roof. HIMS also noted that patients can access all dose strengths of Wegovy in a high-quality pen, available for self-pay patients (without insurance or government aid). Furthermore, in a shareholder letter issued on May 5, 2025, Hims expressed excitement over its 'innovative partnerships' that offer consumers greater choice within the weight-loss category. The company also highlighted its long-term collaboration with Novo Nordisk to expand affordable access to proven obesity care. This partnership was touted as a way to strengthen the platform's offerings with Novo Nordisk's innovative pipeline, enabling Hims to serve more customers, expand access to clinically proven treatments, and drive stronger health outcomes. Finally, in its Q1FY25 quarterly report filed on May 5, Hims & Hers stated that its GLP-1 offerings generated about $230 million in Online segment Revenue, with a significant majority coming from personalized doses. However, subsequent events (mentioned below) reveal that the defendants failed to disclose that the platform had started engaging in 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.' Plaintiffs' Arguments The plaintiffs maintain that the defendants deceived investors by lying and withholding critical information about the business practices and prospects during the Class Period. Importantly, the defendants are accused of misleading investors about their illegal practices used to boost Online sales, as well as the potential termination of their contract with Novo Nordisk. The information became clear before the market opened on June 23, 2025, when Novo Nordisk issued a press release announcing that it was terminating its partnership with Hims & Hers. Novo Nordisk stated that it was ending the collaboration because Hims & Hers had engaged in dishonest promotional tactics and sold illegitimate, copycat versions of Wegovy, thereby putting patient safety at risk. Moreover, Novo Nordisk explained that HIMS 'failed to adhere to the law, which prohibits mass sales of compounded drugs under the false guise of personalization.' Following the news, HIMS stock collapsed by 34.6% that same day. To conclude, the defendants misled investors by engaging in deceptive and illegal practices to boost Online sales, which ultimately led to the termination of their lucrative contract with Novo Nordisk. Despite these issues, HIMS stock has surged over 108% so far this year.
Business Upturn
4 days ago
- Business
- Business Upturn
HIMS SECURITIES NEWS: Did Hims & Hers Health, Inc. (NYSE:HIMS) Commit Securities Fraud? Contact BFA Law by August 25 Class Action Deadline
NEW YORK, July 20, 2025 (GLOBE NEWSWIRE) — Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Hims & Hers Health, Inc. (NYSE: HIMS) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Hims & Hers, you are encouraged to obtain additional information by visiting: Investors have until August 25, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors who purchased Hims & Hers securities. The case is pending in the U.S. District Court for the Northern District of California and is captioned Sookdeo v. Hims & Hers Health, Inc., et al. , No. 25-cv-05315. A subsequent complaint alleging substantially similar claims was also filed and is captioned Yaghsizian v. Hims & Hers Health, Inc., et al. , No. 25-cv-05321. Why was Hims & Hers Sued for Securities Fraud? Hims & Hers operates a telehealth platform that provides consumers with access to online consultations with licensed healthcare professionals, prescription medications, and a range of wellness products. On April 29, 2025, Hims & Hers and Novo Nordisk announced a 'long-term collaboration' starting with the immediate sale of Novo Nordisk's popular weight loss drug Wegovy on the Hims & Hers platform. The active ingredient in Wegovy is semaglutide. As alleged, Hims & Hers touted and misrepresented to investors the nature of its partnership with Novo Nordisk, including asserting that under the terms of the agreement His & Hers could offer both Wegovy and compounded semaglutide to its customers. Hims & Hers also allegedly represented to investors that its sale of compounded semaglutide complied with FDA regulations. The Stock Declines as the Truth is Revealed On June 23, 2025, Novo Nordisk announced that it was terminating the partnership, 'based on Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk' and alleged that Hims & Hers 'failed to adhere to the law which prohibits mass sales of compounded drugs.' On this news, the price of Hims & Hers stock fell $22.24 per share, or more than 34%, from $64.22 per share on June 20, 2025 to $41.98 per share on June 23, 2025. Click here for more information: What Can You Do? If you invested in Hims & Hers you may have legal options and are encouraged to submit your information to the firm. All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses. Submit your information by visiting: Or contact:Ross Shikowitz [email protected] 212-789-3619
Associated Press
6 days ago
- Business
- Associated Press
CLASS ACTION NOTICE FOR HIMS: Kessler Topaz Meltzer & Check, LLP Reminds Hims & Hers Health, Inc. Shareholders of Securities Fraud Class Action Lawsuit and Encourages Investors With Losses to Contact the Firm
RADNOR, PA - July 18, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that securities class action lawsuits have been filed in the United States District Court for the Northern District of California against Hims & Hers Health, Inc. ('Hims & Hers') ( NYSE: HIMS ) on behalf of those who purchased or otherwise acquired Hims & Hers securities between April 29, 2025, and June 23, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is August 25, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Hims & Hers losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaints allege that, throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) Hims & Hers was engaged in the 'deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk;' (2) as a result, there was a substantial risk that Hims & Hers' collaboration with Novo Nordisk would be terminated; and (3) that, as a result of the foregoing, Defendants' positive statements about the company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis. Please CLICK HERE to view our video or copy and paste this link into your browser: THE LEAD PLAINTIFF PROCESS: Hims & Hers investors may, no later than August 25, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Hims & Hers investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.
Newsweek
6 days ago
- Business
- Newsweek
Weight-Loss Drugs Telehealth Platform Hims & Hers Hit With New Lawsuit
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A stockholder has filed a derivative lawsuit against the board of directors of Hims & Hers, the fast‑growing telehealth platform best known for men's and women's health products—especially its weight‑loss therapies. The suit Jones vs. Dudum names board members and CEO Andrew Dudum in U.S. District Court in San Francisco, arguing that a high-profile partnership gone awry has left the company—and its shareholders—on shaky ground. Newsweek contacted Francis J. Flynn, Jr., Attorney at the Law Office of Francis J. Flynn, Jr. representing Steven Jones in this derivative action on behalf of Hims & Hers Health, Inc., via email on Tuesday for comment. Attorneys for Dudum or the others directors was not listed at time of publication. Dudum, responding to the deal's collapse, last month said Hims & Hers adhered to legal frameworks and accused, accused the drugmaker involved of attempting to steer the company's patients toward its own products. "We refuse to be strong-armed," he said. The other company in the deal Novo Nordisk did not respond to Dudum's remarks, when contacted by Reuters on June 23. Stock image of semaglutide injections. A recent TikTok explained whether you would gain back double the weight after going off weight-loss drugs. Stock image of semaglutide injections. A recent TikTok explained whether you would gain back double the weight after going off weight-loss drugs. Photo by Aplott / Getty Images Why It Matters The dispute raises critical questions for the telehealth industry, including regulatory gray zones such as how far can compounding pharmacies can go under "personalization" rules, especially when dealing in high-demand drugs? And what responsibility do boards have to fully evaluate regulatory risk—even when pursuing innovative deals? What To Know The newly filed lawsuit is not a standard stock drop claim but a derivative suit, meaning it is brought by a shareholder on behalf of the company. A derivative suit places emphasis not just on damages to investors, but on the breach of fiduciary duty owed to the company itself. If the suit is successful, any recovery—whether from settlements or judgments—will go to Hims & Hers, not directly to the suing shareholder. Jones vs. Dudum is the latest of three investor‑initiated lawsuits tied to the collapse of the Wegovy deal. Two earlier securities class action suits were filed last month by investors seeking damages for the sharp drop in share price following the June meltdown. Unlike those class actions—which typically focus on misrepresentation to shareholders—the derivative suit alleges governance failures and corporate mismanagement at the board level. The plaintiff in the new suit alleges that the board and management disseminated misleading statements about the health of a partnership and the legality of its business model, ultimately harming the company's interests. The claim hinges on two major points: first, that the board approved a deal without sufficient due diligence into regulatory exposure; second, that public communications misled investors about the risk of compounding semaglutide and the deal's longevity. Ozempic and rival products like Danish pharmaceutical giant Novo Nordisk's Wegovy have fueled a national obsession with medical weight loss. But pandemic-related demand spikes and supply constraints prompted the FDA to allow compounding pharmacies to produce semaglutide during shortages. While legal, these compounded drugs are not subject to the same regulatory oversight, raising red flags for safety advocates and brand-name drugmakers. Once the shortage was lifted in February 2025, the FDA removed approved semaglutide from its shortage list, signaling that broad compounding should cease. Instead, many including Hims & Hers continued dispensing compounding-based copies under the contested "personalization" rationale—offering customised semaglutide dosages providers argue are tailored to individual patient needs. On April 29, 2025, Hims & Hers and Novo Nordisk unveiled a landmark collaboration to bring Wegovy—Novo's blockbuster semaglutide-based weight‑loss injection—to Hims & Hers' digital storefront. The goal was to tap into soaring demand for obesity treatments via a trusted telehealth interface. At the time, Hims & Hers had also been offering compounded semaglutide, a so-called "knock‑off" version of Wegovy, legally produced by compounding pharmacies during the FDA's declared shortage of brand‑name drugs—an arrangement that Novo Nordisk had publicly criticized and challenged as risky and unregulated. In an abrupt June 23 announcement—only two months after the deal was unveiled—Novo Nordisk severed the partnership. The company accused Hims & Hers of "deceptive promotion," arguing that its compounding operations went beyond legal allowances and threatened patient safety. Hims & Hers' stock plummeted. What People Are Saying Him & Hers Founder, Andrew Dudum said in his post on X in June: "In recent weeks, Novo Nordisk's commercial team increasingly pressured us to control clinical standards and steer patients to Wegovy regardless of whether it was clinically best for patients", adding "We refuse to be strong-armed by any pharmaceutical company's anticompetitive demands that infringe on the independent decision making of providers and limit patient choice." Dudum said of the prospect of legal action: "They might take legal action. Others might take legal action. Again, when things are hurting their bottom line in this way, people do all types of things." Dave Moore, executive vice president U.S. operations at Novo Nordisk said in a June 23 release about the deal collapse: "We terminated the deal to protect patients living with obesity", and reaffirmed that only "...authentic, FDA‑approved and regulated Wegovy should be prescribed." He added: "We will work with telehealth companies to provide direct access to Wegovy that share our commitment to patient safety—and when companies engage in illegal sham compounding that jeopardizes the health of Americans, we will continue to take action." And in a Novo corporate statement on July 14, the company said: "Hims & Hers Health, Inc. has failed to adhere to the law which prohibits mass sales of compounded drugs under the false guise of 'personalization' and are disseminating deceptive marketing that put patient safety at risk." What Happens Next The derivative lawsuit is in its early stage. No hearings or settlement discussions have been reported.
